We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000012:SSECSG Holding Co., Ltd. Analysis

Data as of 2026-03-14 - not real-time

CN¥4.87

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The stock is trading just above its 20‑day and 200‑day moving averages, with a neutral RSI around the mid‑50s, while the MACD has slipped into a bearish crossover and volume is on a downtrend, suggesting limited short‑term upside. Volatility is elevated at over 40% for the past month, yet the beta is exceptionally low, indicating the share moves largely independent of broader market swings.
Fundamentally, revenue is growing modestly at about 5% YoY, but the company posted a negative profit margin and a loss per share, while carrying a high debt load (debt‑to‑equity >75%). The dividend yield of 1.44% looks attractive, but the payout ratio near 80% and negative free cash flow raise concerns about sustainability. A discounted cash‑flow model values the firm at roughly 2.4 CNY, far below the current price of 4.9 CNY, implying the stock is overvalued despite a forward PE of around 9.5. Investors should weigh the short‑term technical weakness against the medium‑term earnings recovery outlook and the long‑term structural opportunities in glass, solar and electronic display segments.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD crossover and decreasing volume
  • Price near technical support but above moving averages
  • High valuation gap vs. DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward EPS turning positive and forward PE modest
  • Growth prospects in solar and electronic glass segments
  • Dividend yield adds income while the stock may correct toward fair value

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Structural industry tailwinds in building and renewable‑energy glass
  • Persistent high leverage and negative ROE
  • Overvaluation relative to intrinsic DCF estimate

Key Metrics & Analysis

Financial Health

Revenue Growth4.90%
Profit Margin-2.63%
P/E Ratio9.5
ROE-2.73%
ROA0.13%
Debt/Equity75.32
P/B Ratio1.1
Op. Cash FlowCN¥1.2B
Free Cash FlowCN¥-613504576

Technical Analysis

TrendNeutral
RSI53.8
SupportCN¥4.54
ResistanceCN¥5.27
MA 20CN¥4.84
MA 50CN¥4.66
MA 200CN¥4.72
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueCN¥2.39
Target PriceCN¥6.30
Upside/Downside29.36%
GradeOvervalued
TypeBlend
Dividend Yield1.44%

Risk Assessment

Beta0.13
Volatility42.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.